How Is Kratom Used? Methods, Effects, and Risks

Kratom is consumed by chewing fresh leaves, brewing dried leaf into tea, swallowing powdered leaf in capsules, mixing powder into food or drinks, and, increasingly, taking concentrated liquid extracts or isolates. The plant’s effects shift depending on dose: small amounts tend to produce stimulation and alertness, while larger amounts lean toward sedation and pain relief. That dual nature is central to understanding both why millions of people seek kratom out and why health authorities remain wary of it.

Traditional Roots and Modern Formats

In Southeast Asia, where the kratom tree (Mitragyna speciosa) grows natively, rural workers have long chewed fresh leaves or brewed them into tea to fight fatigue during manual labor, ease common aches, and accompany social gatherings.¹ Chewing raw leaf remains common in Thailand and Malaysia, but it is not the way most Western users encounter kratom. In the United States and Europe, dried leaf is ground into a fine green powder and sold in bags, capsules, or tablets. You can stir the powder into juice, blend it into a smoothie, or pack it into gel capsules to avoid the bitter taste.

The product landscape has expanded rapidly. Early on, virtually everything on the market was whole-leaf material in one form or another. More recently, vendors have introduced concentrated extracts, liquid “shots,” and purified alkaloid isolates that deliver far higher doses of kratom’s active compounds per serving.² This distinction between plain leaf products and concentrated ones matters a great deal for risk, as discussed below.

Who Uses Kratom and Why

Surveys of U.S. kratom consumers paint a fairly consistent picture of motivations. In one large online survey, pain relief was the most common reason, endorsed by about half of respondents. Roughly a fifth used kratom for anxiety, PTSD, or depression, about one in ten for energy or focus, and another one in ten specifically to cut down on opioid use or manage withdrawal. Among those who used it as a substitute for opioids, over 90% said it helped with pain, reducing opioid intake, and easing withdrawal symptoms.³

A more detailed analysis identified at least four distinct groups of U.S. kratom consumers. The largest group, about a third of users, took kratom primarily for chronic pain. The smallest group, roughly a fifth, used it as a long-term replacement for other substances. The remaining two groups used kratom mainly for anxiety and depression management or for recreational purposes. The recreational-leaning group with more severe anxiety and depressive symptoms also showed higher rates of problematic kratom use.⁴

People who take kratom to reduce opioid use tend to differ from other kratom users in some telling ways. They report higher daily doses, more frequent use, and more withdrawal symptoms. They are also more likely to have histories of back pain, depression, and panic attacks, and more likely to have used opioids, benzodiazepines, and cocaine in the past year.⁵ This group, in other words, is managing more complex health situations, and their heavier use patterns carry proportionally higher risk.

The Biphasic Effect

One of kratom’s most distinctive features is that low doses and high doses produce noticeably different effects. At lower amounts, users typically feel more alert, sociable, and energized. At higher amounts, the experience shifts toward sedation, pain relief, and a feeling sometimes compared to opioid warmth.⁶ This is not a vague folk observation; it tracks with how the plant’s alkaloids interact with different receptor systems at different concentrations.

Mitragynine, the most abundant alkaloid in kratom leaf, acts on opioid receptors in the brain but also engages adrenergic and serotonergic pathways.⁷ At low concentrations, the adrenergic stimulation tends to dominate, producing the energizing effects. As the dose climbs, opioid receptor activity takes over, bringing sedation and analgesia. The body also converts some mitragynine into 7-hydroxymitragynine, a metabolite that binds opioid receptors much more strongly.⁸ That conversion is one reason the effects can intensify in ways people don’t always predict.

Plain Leaf Versus Concentrated Products

This is where risk assessment gets complicated. The total alkaloid content of raw kratom leaf is roughly 2 to 5% by weight. Concentrated extracts can pack five to 50 times that amount into the same volume. Purified compounds, especially semi-synthetic 7-hydroxymitragynine, carry a meaningfully higher risk for dependence and overdose compared to whole-leaf preparations.⁹

Think of it like the difference between chewing a coca leaf and snorting refined cocaine, though the gap is not quite that extreme. With plain leaf powder, the alkaloid dose is self-limiting to some degree: you have to consume a large volume of bitter plant matter to reach very high doses, and nausea often kicks in before you get there. With a concentrated extract shot, that built-in ceiling disappears. The rapid growth in extract and isolate products is one reason researchers and clinicians are paying more attention to kratom-related harms than they were a decade ago.

Dependence and Withdrawal

Kratom can produce physical dependence, but how quickly that happens and how severe it gets varies enormously based on dose, frequency, and product type. An expert forum concluded that moderate daily use of plain leaf material, something like 2 grams once or twice a day, generally does not lead to significant withdrawal. Withdrawal becomes more common at higher intake, likely exceeding about 300 milligrams of mitragynine per day, taken over an extended period. Even among heavy users consuming three or more times daily, withdrawal is not consistently reported by everyone.¹⁰

When withdrawal does occur, it tends to be milder than withdrawal from traditional opioids, sedatives, or stimulants. Symptoms can include muscle aches, runny nose, sleep difficulty, hot flashes, decreased appetite, diarrhea, restlessness, irritability, and low mood.¹¹ Some of these overlap with opioid withdrawal while others resemble stimulant or sedative discontinuation, which makes sense given kratom’s action on multiple receptor systems.

That said, the picture is not entirely reassuring. A study of regular users with over six months of use found that more than half developed what researchers classified as severe dependence, with the rest showing moderate dependence.¹¹ More recent research using formal diagnostic criteria found that most users scored in the mild-to-moderate range for both withdrawal and use disorder symptoms, and that how often you dose matters more than how much you take at once.¹² Frequency, not just quantity, is the bigger driver of dependence.

Liver Injury

Kratom has been linked to drug-induced liver injury in a number of case reports and small case series. The U.S. Drug Induced Liver Injury Network identified 11 cases attributed to kratom, noting a recent increase. Most patients were men, with a median age of 40. All developed jaundice, typically about two weeks after starting kratom, and most required hospitalization. All eventually recovered.¹³

Liver biopsy findings in these cases show a distinctive pattern of bile buildup and inflammation.¹⁴ More serious outcomes, including acute liver failure and organ dysfunction, have been documented in case reports as well.¹⁵ It remains unclear whether liver injury is caused by mitragynine itself, by other alkaloids, by contaminants in unregulated products, or by some combination. The relatively small number of reported cases compared to the size of the user population suggests this is uncommon, but the unpredictability of who will be affected makes it a real concern.

Other Adverse Effects

Beyond liver injury, kratom use has been associated with cardiovascular, gastrointestinal, neurological, and psychiatric effects. Nausea, constipation, and appetite loss are among the more common complaints with regular use. More concerning are reports of rapid heart rate and agitation.¹⁶ Data from U.S. poison control centers between 2011 and 2017 showed that among kratom-only exposures, about 86% resulted in at least one clinical effect, with agitation and rapid heart rate being the most common, each occurring in roughly one in five cases.¹⁷

Chronic heavy use can also produce visible skin changes. Case reports describe gray-blue patches of hyperpigmentation developing on sun-exposed areas of the face, chest, arms, and hands. Biopsies of affected skin reveal melanin deposits in the dermis, suggesting kratom somehow stimulates or redistributes pigment production.¹⁸ This side effect appears to be associated with prolonged, heavy consumption and resolves when use stops, but it can be cosmetically distressing.

Drug Interactions

One of the less-discussed but potentially serious risks of kratom is its ability to interfere with how your body processes other medications. Mitragynine is metabolized primarily by the liver enzyme CYP3A4, with smaller contributions from CYP2D6 and CYP2C9.¹⁹ But kratom alkaloids don’t just get processed by these enzymes; they also inhibit them, which can slow down the metabolism of other drugs that rely on the same pathways.

Laboratory studies have found that mitragynine is a potent inhibitor of CYP2D6, an enzyme responsible for metabolizing a wide range of common medications including many antidepressants, antipsychotics, beta-blockers, and some opioids. Another kratom alkaloid, corynantheidine, shows similar inhibitory potency against CYP2D6.²⁰ Kratom extracts also inhibit CYP2C9 and CYP3A to a lesser extent, and because CYP3A is present in the gut wall as well as the liver, the concentrations of mitragynine in the intestine after oral consumption could be high enough to block CYP3A activity there.²⁰

What this means in practice: if you take kratom alongside a prescription drug that is cleared by CYP2D6, the drug could build up in your system to higher-than-expected levels, amplifying both its therapeutic effects and its side effects. This is especially worrying for medications with narrow safety margins. Anyone combining kratom with prescription medications should be aware of this interaction potential, though few doctors will think to ask about kratom use, and few kratom users think to mention it.

Contamination and Product Quality

Because kratom is sold as a dietary supplement in the United States and is not subject to the same testing and manufacturing standards as pharmaceuticals, product quality varies wildly. An analysis of kratom products purchased in the Chicago area found that nearly all tested positive for bacteria or fungi. Multiple products contained significant levels of nickel, lead, and chromium.²¹ The mitragynine content also varied considerably between products, meaning that two packages labeled similarly could deliver meaningfully different doses.

Some states have enacted their own regulations requiring good manufacturing practices and proper labeling for kratom products, but federal oversight remains limited.²² The inconsistency makes it difficult for consumers to know exactly what they are getting, even from vendors they trust. Contaminants may account for some of the liver injuries and other adverse effects attributed to kratom itself, but teasing apart the effects of the plant from the effects of impurities in unregulated products is challenging.

Kratom During Pregnancy

Kratom use during pregnancy can cause neonatal abstinence syndrome, the same withdrawal condition seen in newborns exposed to opioids in the womb. Case reports describe infants born to mothers who drank kratom tea daily requiring treatment with opioid medications for withdrawal symptoms after birth.²³ The withdrawal cannot be detected by standard toxicology screens, meaning hospital staff may not identify the cause unless the mother discloses her kratom use.²⁴ This is a particular concern for women who use kratom to self-manage opioid dependence during pregnancy, believing it to be a safer alternative.

Detection in Drug Tests

Standard workplace and clinical drug screens do not detect kratom. Mitragynine and its metabolites do not trigger positive results on immunoassay panels designed for opioids, amphetamines, or other common drugs of abuse. Identifying kratom use requires specialized laboratory techniques such as liquid chromatography-mass spectrometry, which is expensive and not routinely ordered.²⁵ For some users, this invisibility on drug screens is part of the appeal: people subject to regular testing for work or legal reasons may turn to kratom precisely because it won’t show up. For clinicians, the flip side is that a patient’s kratom use can go unrecognized even when it is contributing to symptoms or drug interactions. The gap in routine detection also means that surveillance data on kratom-related harms almost certainly undercount the actual prevalence of problems.

The Self-Treatment Question

A large part of kratom’s popularity stems from people using it to manage conditions that conventional medicine hasn’t adequately addressed for them, whether chronic pain, anxiety, depression, or opioid dependence. Case reports have documented individuals successfully using kratom to self-treat opioid withdrawal.²⁶ And survey data consistently shows that most users report it helps them with the problems they are trying to address.³

The tension here is real and unresolved. For someone choosing between kratom and illicit fentanyl, or between kratom and untreated chronic pain that is destroying their quality of life, the risk calculus looks quite different than it does from a clean regulatory perspective. At the same time, self-treatment with an unregulated, variable-quality botanical product that carries dependence risk and can interact dangerously with medications is genuinely not the same as using an evidence-based, dose-controlled treatment under medical supervision. The honest assessment is that kratom occupies a gray zone: it has pharmacological activity that is plausible for the conditions people use it for, but the lack of standardized dosing, quality control, and long-term safety data means users are running an experiment on themselves without the safety net that clinical medicine, imperfect as it is, provides.

Legal Status Around the World

Kratom’s legal standing is a patchwork. In the United States, it is not federally scheduled, though the FDA has not approved it for any medical use and has issued warnings about its safety. Several U.S. states and municipalities have banned it outright, while others have passed laws requiring labeling standards and age restrictions on sales. Internationally, kratom is classified as an illicit substance in several European and Asian countries, while other nations have no regulations addressing it at all.²² Thailand, where kratom has been used for centuries, legalized it in 2021 after decades of prohibition, an acknowledgment of cultural practice and a shift toward regulation rather than criminalization.

The regulatory uncertainty creates problems on multiple fronts. Vendors operate without consistent quality standards, consumers cannot easily verify what they are buying, and researchers face bureaucratic obstacles that slow down the clinical studies that could actually clarify kratom’s risks and potential benefits. For now, you are essentially navigating this on your own, informed by a growing but still incomplete body of evidence.